source
- LifeMine Therapeutics secures $263 million to develop safer transplant immunosuppressantLifeMine Therapeutics announced it has raised a total of $263 million through two venture financing rounds. The capital, which includes a newly disclosed $75 million Series D round, will be used t…
- BioVie’s Parkinson drug data prompts 50% stock drop as company shifts to composite endpointBioVie announced phase 2 results for its experimental Parkinson’s therapy bezisterim, saying the data suggest a meaningful advance in treating the disease. Investors reacted sharply, wiping out ro…